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pro-inflammatory cytokine and chemokine production by primary renal tubular epi-
thelial cells and monocytes/macrophages. ConClusions: These findings demon-
strate that administration of forskolin is beneficial for controlling the development 
of UPEC mediated acute pyelonephritis in mice. The protective effect of forskolin 
(via cAMP activation) in this experimental acute pyelonephritis can be explained at 
least in part by limiting excessive inflammatory responses through acting on both 
renal parenchymal and inflammatory cells.
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objeCtives: To determine if blocking C5aR could effectively protect mice from UPEC 
induced kidney infection. Methods: A well-established mouse model of ascending 
UTI leading to kidney infection was employed. C5aR antagonist (C5aRa, W54011) 
(250mg/kg) was given before the induction of infection by i.p. injection. Kidney 
infection was assessed in C5aRa or control reagent treated mice at 6, 24, 72h after 
bladder inoculation of UPEC. Bacteria load in kidneys was analysed by the agar plate 
assay. Tissue damage was assessed by histopathology. Leukocytes infiltration was 
analysed by immunochemical staining, tissue MPO activity assay and flow cytom-
etry. Renal synthesis of cytokines/chemokines was analysed by RT-PCR. Results: 
Compared to control reagent treated mice, C5aRa treated mice, either from B6 or 
BALB/c background, exhibited significantly lower rates of kidney infection (B6: 37.5% 
vs 100% [n= 16], BALB/c: 26% vs 87% [n= 15]), reduced kidney tissue damage and gene 
expression of KC, IL-6 and TNF-α in kidney tissues. The reduction of kidney infection 
and tissue damage resulting from C5aR blockade was more profound at 48h and 
72h post infection. C5aR blockade led a small reduction of neutrophil infiltration at 
6h, but had no apparent effect on late time point. ConClusions: C5aR blockade 
effectively protected mice from UPEC-induced kidney infection suggesting that C5aR 
signal is a critical pathogenic factor in UTIs, thus representing a promising target 
for treating or preventing human UTIs.
URinaRy/Kidney disoRdeRs – Cost studies
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objeCtives: The increasing prevalence of patients with end-stage renal disease 
in Malaysia is driving up the costs of dialysis care dramatically. Several studies 
have projected significant cost savings by increasing the proportion of patients 
on peritoneal dialysis (PD). This study investigates the five-year health care 
budget impact of variable distribution of adult patients treated with PD and in-
center hemodialysis (ICHD) on government funding in Malaysia. Methods: An 
Excel®-based budget impact model was constructed to assess dialysis-associ-
ated costs when changing dialysis modalities between PD and ICHD. The model 
incorporates the current modality distribution and accounts for Malaysian govern-
ment dialysis payments and EPO costs. Epidemiological data, including dialysis 
prevalence, incidence, mortality, and transplant rate from Malaysian renal registry 
reports, were used to estimate the dialysis patient population for the next five years. 
The baseline scenario assumed a stable distribution of PD (8%) and ICHD (92%) 
over five years. Alternative scenarios included the prevalence of PD increased by 
2.5%, 5.0%, and 7.5% or decreased 1% yearly over five years. All four scenarios were 
accompanied with commensurate changes in ICHD. Results: Under the current 
best available cost information, an increase in the prevalent PD population from 8% 
in 2014 to 18%, 28%, or 38% in 2018 is predicted to result in five-year cumulative sav-
ings for the Malaysian government of RM13.9 million, RM27.9 million, and RM41.96 
million, respectively. If the prevalent PD population were to decrease from 8% in 
2014 to 4.0% by 2018, the total expenditure for dialysis treatments would increase 
by RM5.6 million over the next five years. ConClusions: Under the best available 
cost information associated with PD and HD paid by the Malaysian government, 
increasing the proportion of patients on PD could result in reduction in dialysis-
associated costs in the future.
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objeCtives: In 2012, 0.3% of Taiwan end-stage renal disease (ESRD) patients 
accounted for 6.64% of National Health Insurance (NHI) dialysis spending. 
We investigated the five-year financial impact of changing the distribution of 
patients undergoing peritoneal dialysis (PD) and in-center hemodialysis (ICHD) 
in Taiwan. Methods: An Excel®-based budget impact model was constructed to 
assess dialysis-associated costs. The model incorporates Taiwan current modal-
ity distribution and accounts for ESRD outpatient and inpatient total health care 
cost. Epidemiological data of ESRD patients from 2000 to 2011 was acquired from 
Taiwan Renal Data System by Taiwan Society of Nephrology. The transplant rate 
was provided by experts in the field. These data were used to estimate dialysis 
population for the next five years. Dialysis costs were obtained by National Health 
Research Institutes (NHRI) Databases for 2008. The baseline scenario assumed a 
stable distribution of PD (10%) and ICHD (90%) over five years. Four scenarios, includ-
the treatment of BPH is lacking. This systematic review registered with PROSPERO 
(registration number: CRD42014007248) aims to provide the evidence for the AE 
associate with tadalafil use in BPH indication. ConClusions: Tadalafil use in BPH 
has now been increasing over the years. The data from published RCTs will help to 
identify the AE associated with its use.
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objeCtives: Dengue fever is a mosquito borne infectious disease that is mainly 
prevalent in tropical and subtropical zones of the world. One of the potential 
complications of dengue fever is acute kidney injury (AKI). Current study aims to 
assess the incidence and risk factors for AKI among dengue patients.  Methods: 
A retrospective review of medical records of dengue infected patients enrolled 
from May 2005 to December 2013 was conducted at a tertiary care hospital in 
Kelantan. Results: Total 124 patient records (male: 63, female: 61) with mean 
age of 29.57± 15.09 were reviewed retrospectively. Out of 124 patients, 104 (83.9%) 
suffered with classical DF, 19 (15.3%) with dengue hemorrhagic fever (DHF) while 
only 1(0.8%) with Dengue shock syndrome (DSS).The prevalence of AKI among 
Dengue patients was found to be 7.2 % (9 patients). On the basis of Acute Kidney 
Injury Network (AKIN) criteria, 2(22%) had stage 1 AKI while remaining 7 (78%) 
had stage 2 AKI. For the purpose of analysis of risk factors for AKI, patients were 
categorized into group I (with AKI) and group II (without AKI). Mann Whitney “U” 
test was used to compare differences between groups. A higher serum creatinine 
(112.39 vs. 56.87; p:0.001), bilirubin (70.81 vs. 48.73; p:0.038), urea (104.50 vs. 58.08; 
p:0.001), WBC (92.25 vs. 59.90; p:0.013) and Hb (90.91 vs. 60.04; p:0.021) levels were 
observed among AKI dengue patients. Though the duration of hospital stay of 
group I was more than group II, but this difference was statistically insignifi-
cant (I=77.33, II= 61.34; p: 0.192). ConClusions: AKI is a least studied and poorly 
understood complication of dengue fever. Such patients are at verge of developing 
DHS/DSS resulting in complicated clinical course and increased mortality. A cau-
tious diagnosis and timely management should be the first and foremost step for 
management of such patients.
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objeCtives: The study aims to determine the different epidemiological factors 
responsible for the cause of hospital readmissions in chronic hemodialysis (HD) 
patients. Methods: Reviewed data of 170 patients with 124 male and 46 female 
patients receiving maintenance HD twice weekly schedule on a Mon/Thu, Tue/Fri, 
Wed/Sat with prevalent adult’s HD patients on period from 1st Jan to Dec 31, 2010 
or continued until close at death, modality change, deviation from HD schedule not 
during a hospital stay, loss to follow-up. Eligible patients were actively recruited who 
were on chronic HD fulfilling the inclusion criteria. ICD-9-CM diagnosis codes were 
used. Results: A total of 170 patients with End-stage renal disease (ESRD) on chronic 
HD included the study cohort. The mean age was 52.4±11.6 years; 27% were women 
with a mean year of patients on hemodialysis of 3.2±2.6. Hypertension 29.3% and 
hypertension with diabetes 26.4% were the leading cause of ESRD and least cause of 
renal failure was seen with polycystic kidney disease, Glomerulonephritis, Interstitial 
nephritis, and others. Hospital readmission was commonly for cardiovascular complications 
62% to infections 31% and other 7%. IHD, Stroke and Congestive heart failure lead to read-
mission and with infection of AV fistula 66% were more commonly seen compared to 
Catheterization. ConClusions: Hypertension is the leading cause for ESRD and car-
diovascular complications were associated with elevated hospital readmission in addition 
to infection. AV fistula is the other common source of infection leading to readmission.
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objeCtives: To investigate the effect of forskolin, on susceptibility/severity of acute 
pyelonephritis and innate immune responses to pathogen using an established 
experimental model of ascending urinary tract infection and primary cell cultures 
(i.e. renal tubular epithelial cells, monocytes/macrophages). Methods: Forskolin 
is produced by the Indian Coleus plant (Coleus forskohlii), which is commonly used 
to raise levels of cyclic AMP (cAMP) in the study and research of cell physiology. 
Forkolin (250mg/kg) was given before the induction of infection by i.p. injection. 
Kidney infection was assessed in forskolin or control reagent treated mice at 6, 24, 
48h after bladder inoculation of UPEC (J96). Bacteria load in kidneys was analyzed 
by the agar plate assay. Tissue damage was assessed by histopathology. Leukocytes 
infiltration was analysed by immunochemical staining, tissue MPO activity assay 
and flow cytometry. Renal synthesis of cytokines/chemokines was analysed by 
RT-PCR. Results: Administration of forskolin significantly reduced bacteria load 
in kidneys and renal tissue damage at both 6 and 24h time points by 10 folds, this 
was associated with reduced intrarenal production of pro-inflammatory cytokines 
and chemokines (e.g. TNF-α , IL-1β , KC, MCP-1) and attenuated intrarenal infiltra-
tion and accumulation of leukocytes (i.e. CD45+. Gr-1+, F4/80+) as well as intrarenal 
myeloperoxidase (MPO) activity. In vitro, forskolinI inhibited LPS or UPEC mediated 
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analysis to compare the two strategies: 1) direct prostate biopsies (TRUS-Bx) and 2) 
percent free PSA testing prior to TRUS-Bx. A systematic review of 855 patients with 
PSA levels of 4.0-10.0 ng/ml and normal DRE enrolled in a single medical institute 
from Jan 2002 to December 2005 was conducted. The outcome measures were the 
incremental cost-effectiveness ratio, and costs were calculated through activity-
accumulation costing based on National Insurance Scheme Bill Size. A one-way 
sensitivity analysis was undertaken. The effectiveness was measured by means of 
the number of detected cases and actual cases (detected cases minus lost cases). 
A threshold analysis is used to illustrate the value of a given variable of which the 
two strategies have equal outcomes or costs. Results: The strategy of percent 
free PSA with TRUS-Bx was dominant and found to be the most cost-effective. The 
incremental cost-effectiveness ratio for free PSA + TRUS-Bx compared with TRUS-Bx 
was USD 3,871.58. Strategy 2 (TRUS-Bx) would be more cost-effective if the cost of 
percent free PSA increased to USD 36.78 or if prostate cancer prevalence increased to 
42%. ConClusions: The use of percent free PSA prior to TRUS-Bx is the most cost-
effective diagnostic strategy and will become more cost-effective as prostate cancer 
prevalence increases in the ageing population and the free PSA test costs down.
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eConoMiC evalUation of the tReatMents foR hyPeRPhosPhateMia 
aMong Patients with ChRoniC Kidney disease: a Review
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objeCtives: The aim of this study was to synthesize the evidence on cost-
effectiveness of treatment for hyperphosphatemia in chronic kidney disease 
Patients. Methods: Using “hyperphosphatemia”,“ chronic kidney disease”, “cost” 
and “economic evaluation” as the keywords for searching in PUBMED. Among 70 
articles, we selected eight related articles for review. Results: First, researches in 
this area are more concentrated in developed countries, such as UK, Canada and 
US. Then, in most countries, they use Markov model based on on the clinical cohort. 
Two articles mentioned that Lanthanum carbonate is associated with consider-
able clinical beneﬁts and good value for money in CKD(£6900/QALY gained, UK). 
One paper point that Lanthanum carbonate is a cost-effective strategy compared 
with Sevelamer in the treatment of ESRD patients with hyperphosphatemia who 
were previously treated with calcium -based binders(for completer population was 
considered, the ICERs of LC versus sevelamer were $15,285/QALY and $9,337/LYS). 
There are five literature suggests, sevelamer is a cost-effective drug for the treat-
ment of hyperphosphatemia in patients with CKD(2.70 QALYs, £25,916 /QALYs,UK; 
18 life-years, Canada). ConClusions: We get different results from the existing 
international studies which couldn’t inform desion makers in China. So, it’s neces-
sary for us to carry out the research in the Chinese setting in the future.
Patient-RePoRted oUtCoMes & Patient PRefeRenCe stUdies
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objeCtives: Among LUTS/BPH patients, OAB symptoms are most troublesome. 
This study investigated the PROs with regards to their symptoms and health-related 
quality of life(HRQoL) and explored the related factors in LUTS/ BPH patients with 
OAB. Methods: This nationwide-observational study was conducted in 30 urol-
ogy centers in Korea during December 2011 to June 2012. BPH patients aged over 50 
years with LUTS(≥ 8 in international prostatic symptom score, IPSS), OAB(≥ 6 in IPSS 
item 2,4,7) and without previous treatment experience were enrolled. Patients were 
surveyed with several validated questionnaires to assess their severity of LUTS(IPSS: 
greater symptoms with higher score), general HRQoL(Euroqol-5 Dimension, EQ-5D: 
lower HRQOL with lower score) and disease specific quality of life(BPH-Question-
naire Korea1, BPH-Q K1: worse HRQoL with higher score, 8 domains). To identify 
the associated factors on PROs, age, comorbidities and clinical characteristics were 
included in the analysis. Results: 749 LUTS/BPH with OAB patients (mean age: 
63.5±8.14) were surveyed. The mean IPSS was 20.1±6.55 (0-35), and the score was 
relatively higher in patients with constipation (p< 0.02). Regarding general HRQoL, 
mean EQ-5D was graded as 0.75±0.14 (0-1). Co-morbidities such as disc, arthritis, 
diabetes, anxiety and higher residual volume of post voiding were shown to have 
a negative impact on general HRQoL (P< 0.05, respectively). The mean BPH-Q K1 
was rated 71.72±27.48 (0-175) in total, and of the 8 domains the highest score was 
recorded in “sexual function”. Patients’ disease related HRQoL was significantly 
affected by comorbid anxiety (P= 0.001). ConClusions: This study showed the neg-
ative impact of LUTS/BPH with OAB on patients’ symptoms and HRQoL. Compared 
to previous studies reporting PROs of BPH itself (IPSS: 15.1, EQ-5D:0.83), BPH patients 
accompanied with OAB in our study showed worse outcomes. This implicates that 
in addition to influential comorbidities, OAB symptoms in BPH should be taken into 
consideration when making treatment decisions in these patients.
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objeCtives: End-stage renal disease (ESRD) affects patient-reported outcomes 
(PRO), including health-related quality of life (HRQoL) and psychological distress. 
HRQoL in dialysis patients measures the physical, social or emotional well-being 
that is affected by ESRD and/or its treatment, and has been increasingly used as 
ing the prevalence of PD increasing by 2%, 3%, and 5% or decreasing by 1.0% each 
year for five years, were analyzed. Results: Under the current best available cost 
information, an increase in the prevalent PD population from 10% in 2014 to 18%, 
22%, or 30% in 2018 is predicted to result in five-year cumulative savings for NHI 
dialysis budget by NT$2,199 million (0.67%), NT$3,299 million (1.0%), and NT$5,498 
million (1.67%), respectively. If the prevalent PD population were to decrease from 
10% in 2013 to 6.0% by 2017, the total payment for dialysis patients would increase 
by NT$1,100 million (0.33%) over the next five years. ConClusions: Under the 
best available cost information associated with PD and HD in Taiwan, incentives to 
increase the proportion of patients on PD could help reduce the total health care 
costs associated with dialysis patients.
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diReCt MediCal Costs foR inPatient tReatMent of ChRoniC Renal 
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objeCtives: This study aims to investigate the direct medical costs for inpatient 
services of chronic renal failure in Guangzhou, China and to explore its deter-
minants. Methods: Direct inpatient services costs data were drawn from the 
reimbursement claim database in Guangzhou City, which covers the entire Urban 
Employee Basic Medical Insurance and Urban Resident Basic Medical Insurance 
enrollees of Guangzhou City. The records of patients who were admitted to hospitals 
between January 2010 and December 2012 with a diagnosis of chronic renal failure 
were all included. Descriptive and regression analyses (through the extended esti-
mating equations approach) were conducted to study the determinants of direct 
hospital costs. Results: A total of 3,524 hospitalisation records were identified. 
The mean (standard deviation, SD) age of patients was 60 (18) years old and the 
majority were male (54%). Patients were more likely to receive inpatient treatments 
at tertiary hospitals (83%), followed by secondary (16%) and primary hospitals (1%). 
The mean (SD) of direct hospital costs per visit was 16,440 (22,677) RMB, among 
which the medication costs account for 38% whereas the out-of-pocket expenses 
(OOP) account for 25% of total direct hospital costs. The mean (SD) length of stay 
was 15 (12) days. Key regression analysis results suggest that age, the type of basic 
medical insurance schemes, hospital levels, length of stay, and whether the patient 
had received kidney transplant were all significantly associated with the total direct 
inpatient services costs (all P< 0.05). Gender was insignificantly associated with the 
total costs (P> 0.10). ConClusions: Both demand and supply side factors were 
significantly associated with the direct inpatient services costs of chronic renal 
failure. The establishment of urban basic medical insurance schemes has reduced 
the financial burden for the insured urban population.
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Wu D.B.C.1, Yee C.H.2, Ng A.C.F.2, Chaiyakunapruk N.1, Lee K.K.C.3
1Monash University Malaysia, Selangor, Malaysia, 2The Chinese University of Hong Kong, Hong 
Kong, Hong Kong, 3Monash University, Kuala Lumpur, Malaysia
objeCtives: Alpha-blockers (AB) or 5-alpha reductase inhibitor (5ARI) monotherapy 
is standard benign prostatic hyperplasia (BPH) treatment. Recently, combination 
therapy with multiple agents e.g. AB (e.g. tamsulosin) plus 5ARI (e.g. dutasteride), 
has gained acceptance due to improved clinical outcomes. However, its cost-effec-
tiveness remains unclear. The study aims to examine health and economic impact of 
combination therapy versus 5ARI monotherapy in a hypothetical cohort of patients 
treated in the public sector of Hong Kong (HK). Methods: A Markov model was 
developed to project the overall cost-savings of combination therapy in a hypotheti-
cal cohort of 1,000 treated in the public health care sector of HK. The model was built 
according to the HK-specific treatment practice. Model parameters including prob-
abilities, costs (2014 HKD), lengths of stay, and utilities were derived from previous 
literatures. Efficacy data was adopted from the 4-year Combination of Avodart and 
Tamsulosin (CombAT) trial. The study was performed from a public payer perspec-
tive. Projected economic and clinical outcomes over 4 years include drug cost, cost 
of BPH treatment, number of acute urinary retention (AUR) and transurethral resec-
tion of the prostate (TURP). Both 1-way and multivariate probabilistic sensitivity 
analyses were undertaken to evaluate robustness of results. Results: Compared 
to tamsulosin, combination therapy could prevent 28 AURs (77.8% reduction) and 69 
TURPs (79.3% reduction) over 4 years. Compared to tamsulosin, combination therapy 
can lead to cost reduction of HKD1,574,079(USD202,690), HKD3,221,084(USD414,780), 
and HKD5,911(USD26,100) due to reduced episodes of AUR, TURP and need of medi-
cal intervention, respectively and additionally a delay in patients’ progression to 
AUR and TURP. The incremental cost per capita is HKD1,045(USD134) over 4 years. 
The results are sensitive to drug cost, drug efficacy and probability of BPH patients 
experiencing TURP. ConClusions: Combination therapy could lead to reduction 
in the number of AUR and TURP and the associated cost.
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deteCtion in Chinese Men with a total Psa of 4.0-10.0 ng/Ml
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objeCtives: The prevalence of prostate cancer in the Chinese population with 
abnormal prostate-specific antigen (PSA) levels of 4.0-10.0 ng/ml is low. The diag-
nosis can only rely on transrectal ultrasound-guided prostate biopsies (TRUS-Bx) 
which may cause major complications. We assess the cost-effectiveness of two 
diagnostic strategies for prostate cancer detection in Chinese men with abnor-
mal PSA levels of 4.0-10.0 ng/ml and normal digital rectal examination of prostate 
(DRE). Methods: Using a decision tree model, we performed a cost-effectiveness 
